Executive Director (Distinguished Scientist), Head of Pathology Strategy - Molec

Executive Director / Distinguished Scientist – Translational Biomarkers Organization

The Translational Biomarkers Organization within Translational Medicine seeks a highly accomplished Executive Director/ Distinguished Scientist to lead enterprise‑wide translational pathology biomarker efforts. The Executive Director will define and implement a unified vision for applying anatomic and digital pathology biomarkers to accelerate drug development across therapeutic areas, while providing decisive leadership to unify pathology related‑ functions and elevate scientific rigor across the organization.

The successful candidate will collaborate closely with Companion Diagnostics to contribute to diagnostic development strategies—particularly the incorporation and validation of digital pathology approaches to enable companion diagnostic solutions. They will work across a highly matrixed organization—partnering with colleagues in the Diagnostic Development Teams, Commercial, Regulatory, Discovery, and other key functions—to deliver cohesive, impactful, and clinically meaningful pathology initiatives.

Responsibilities

• Define the company-wide pathology and digital/computational pathology biomarker strategy, in collaboration with key cross‑functional partners, with a primary focus on oncology and immunology, but extending across all therapeutic areas.
• Coordinate pathology and pathology‑related work across the horizon of drug development, from preclinical programs to post‑marketing, in collaboration with cross‑functional partners.
• Manage anatomic pathologists working within the Translational Biomarkers organization, including the Molecular Pathology biomarker laboratory lead, to foster scientific excellence and ensure alignment of pathology support with assay development.
• Collaborate with internal digital image analysts on the fit‑for‑purpose development and application of advanced AI/ML image analysis capabilities to support therapeutic programs.
• Ensure application of standards and quality frameworks aligned with GLP and CAP/CLIA requirements for clinical laboratory operations.
• Serve as a strategic partner to Companion Diagnostics to contribute to co‑development strategies and assay and image analysis algorithm validation plans for pathology‑driven CDx programs.
• Collaborate with biomarker leads in each therapeutic area to identify pathology‑enabled decision points and translate these into program‑level biomarker strategies.
• Build and manage external collaborations with academic, technology, and industry partners to advance digital and computational pathology innovation and accelerate clinical application.
• Communicate scientific insights, program impact, and strategic recommendations to internal stakeholders; represent the organization through scientific presentations and publications.

Education

Doctor of Medicine (MD) or MD/PhD required, with specialized training in Anatomic Pathology.

Required Experience and Skills

• 10+ years of experience, including 5+ years of experience in a pharmaceutical or biotechnology setting.
• Experience in clinical biomarker development and implementation of biomarker assays to support clinical trials.
• Recognized leader in Anatomic Pathology with extensive experience applying digital and computational pathology approaches to translational biomarker questions.
• Knowledge of GLP and CAP/CLIA regulatory frameworks and experience ensuring compliance within clinical laboratory environments.
• Proven ability to lead cross‑functional and matrixed teams, manage multiple high‑priority programs, and maintain scientific rigor in fast‑paced settings.
• Excellent communication skills with a record of impactful scientific publications and presentations.
• Experience with oversight of high‑performing scientific teams, including direct management of scientists and physician‑scientists.

Preferred Experience and Skills

• Extensive knowledge of drug development and clinical trial conduct.
• Experience with Companion diagnostic development, especially diagnostic development incorporating digital pathology measures.
• Familiarity with advanced tissue‑based spatial profiling technologies (e.g., multiplex IF, multiplex chromogenic IHC, spatial transcriptomics, etc.).
• Knowledge of commonly deployed commercial image acquisition systems and commercial or open‑source image analysis software.

Required Skills

Biomarkers, Clinical Judgment, Clinical Operations, Communication, Diagnostics Development, Digital Pathology, Leadership, Pathology, People Leadership, Strategic Planning, Team Collaboration.

Preferred Skills

Current Employees apply HERE
Current Contingent Workers apply HERE

US and Puerto Rico Residents Only

Our company is committed to inclusion, ensuring that candidates can engage in a hiring process that exhibits their true capabilities. Please click here if you need an accommodation during the application or hiring process.

EEO Statement

As an Equal Employment Opportunity Employer, we provide equal opportunities to all employees and applicants for employment and prohibit discrimination on the basis of race, color, age, religion, sex, sexual orientation, gender identity, national origin, protected veteran status, disability status or other applicable legally protected characteristics. As a federal contractor, we comply with all affirmative action requirements for protected veterans and individuals with disabilities. For more information about personal rights under the U.S. Equal Opportunity Employment laws, visit: EEOC Know Your Rights, EEOC GINA Supplement, Learn more about your rights, including under California, Colorado and other U.S. State Acts.

Compensation and Benefits

The salary range for this role is $310,900.00 - $489,400.00. The successful candidate will be eligible for annual bonus and long‑term incentive, if applicable. We offer a comprehensive package of benefits including medical, dental, vision, healthcare, retirement benefits (401(k)), paid holidays, vacation, and compassionate and sick days.

Location and Working Model

US and Puerto Rico Residents Only. U.S. Hybrid Work Model: Effective September 5, 2023, employees in office‑based positions in the U.S. will be working a hybrid work consisting of three days on‑site per week, Monday‑Thursday, with Friday remote, unless business critical tasks require on‑site presence.

Application Deadline

Job posting end date: 04/23/2026.

1. Additional information about qualification may be available upon request.

#J-18808-Ljbffr